Epigenetic markers in rectal cancer

Area of Science:

• Epigenetics
• Oncology
• Molecular Diagnostics

Background:

• Rectal cancer management relies on accurate risk assessment for treatment decisions.
• Current monitoring for recurrence can be invasive and resource-intensive.
• Identifying patients who can safely avoid adjuvant therapies is a clinical challenge.

Purpose of the Study:

• To investigate DNA methylation patterns as potential biomarkers in rectal cancer.
• To evaluate the utility of these methylation changes for screening, recurrence monitoring, and predicting treatment response.
• To explore the possibility of de-escalating therapy for low-risk rectal cancer patients.

Main Methods:

• Analysis of DNA methylation profiles in rectal cancer patient samples.
• Correlation of methylation patterns with clinical outcomes, including recurrence and treatment response.
• Validation of identified methylation markers.

Main Results:

• Specific DNA methylation changes were identified in rectal cancer.
• These alterations demonstrated potential as screening markers.
• Methylation patterns showed promise in predicting disease recurrence and guiding adjuvant therapy decisions.

Conclusions:

• DNA methylation analysis offers a novel approach for rectal cancer screening and recurrence surveillance.
• Methylation biomarkers can aid in personalizing treatment by identifying patients unlikely to benefit from (neo)adjuvant therapies.
• This approach may reduce treatment-related morbidities in select rectal cancer populations.